Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Common Warts, HPV (Human Papillomavirus), Periungual Warts, Plantar Warts
Interventions: Sensitizing DPCP Ointment, Treatment DPCP Ointment; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Miami, Florida • Oakbrook Terrace, Illinois • Indianapolis, Indiana + 1 more

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Aurora, Colorado • Durham, North Carolina

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: Return to Sport
Interventions: CASE; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 10 Years to 22 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Venous Thromboembolism, Bleeding
Interventions: Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing; Genetic · Other
Lead sponsor: Gwen McMillin; Other
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Interventions: surveys, Blood draw, Transvaginal ultrasounds; Behavioral · Other · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Diabetic Foot Ulcer, Pressure Ulcer, Venous Leg Ulcer, Trauma Injury, Skin Tear, Chronic Ulcer
Interventions: RD1 System; Device
Lead sponsor: RedDress Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Butler, Pennsylvania

Conditions: Plantar Fasciitis
Interventions: platelet rich plasma, corticosteroid injection; Biological · Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Bernadino, California

Conditions: Candidemia
Interventions: Not listed
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Birmingham, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more

Conditions: Respiratory Syncytial Virus
Interventions: Nasal swab sampling, Blood sampling, Diary cards; Procedure · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 6 Years
Enrollment: 2,409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 9
States / cities: Oakland, California • Sacramento, California • Santa Clara, California + 5 more

Conditions: Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases, Pathologic Processes
Interventions: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test; Device
Lead sponsor: Dragonfly Research, LLC; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Wellesley, Massachusetts

Conditions: Glioblastoma Multiforme
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Surgery, Hemoglobin
Interventions: Pulse CO-Oximetry Technology, Blood draw; Device · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: In Utero Procedure Affecting Fetus or Newborn
Interventions: KARL STORZ fetoscope arm; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gestational Diabetes Mellitus
Interventions: Standard Glucola GCT, Twizzlers challenge; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 617 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ascites, Liver Cirrhosis, Hypertension, Portal
Interventions: Proximal Splenic Artery Embolization; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Age Related Macular Degeneration
Interventions: ranibizumab, dexamethasone and verteporfin, Ranibizumab; Drug
Lead sponsor: Bay Area Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more

Conditions: Lung Transplant
Interventions: Procedure; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Cleveland, Ohio

Conditions: Sarcoidosis
Interventions: Abatacept; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: IgG4-related Disease
Interventions: Abatacept; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Transplant Recipient
Interventions: Belatacept, Abatacept; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide, Ramipril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more

Conditions: Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions: Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab); Biological · Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Search by objective public record fields.

Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

FITting Non-invasive Tests in Lynch Syndrome Surveillance

Clinical Assessment of Sports Exertion

Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1

Treatment of Plantar Fasciitis With Platelet Rich Plasma

Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Accuracy of Pulse CO-Oximetry Technology in Characterizing Noninvasive SpHb

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

The Use of Karl Storz Curved Fetoscope (11508aak) and Its Straight Version (11506akk) for In-utero Surgery

Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial

Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

PREDICT Cytomegalovirus (CMV)

Safety Study of Abatacept to Treat Refractory Sarcoidosis

Safety and Efficacy of Abatacept in IgG4-Related Disease

Abatacept Conversion in Kidney Transplantation

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.